AZNAstraZenecaSigning up patients
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Chronic Lymphocytic Leukaemia · Small Lymphocytic Lymphoma · Mantle-cell Lymphoma · Large B-cell Lymphoma · B-cell Non-Hodgkin Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 408 (planned)
- Started
- Jan 30, 2025
- Main results expected
- May 20, 2030
- Fully finished
- May 20, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Adverse Events, Serious Adverse Events and Adverse Events of Special Interest
Measured over: Up to 6 years 4 months
Number of Participants with Dose Limiting Toxicity (DLTs)
Measured over: Up to 2 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06564038 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC